Literature DB >> 31446064

COPD Assessment Test in Bronchiectasis: Minimum Clinically Important Difference and Psychometric Validation: A Prospective Study.

David De la Rosa Carrillo1, Casilda Olveira2, Marta García-Clemente3, Rosa-María Girón-Moreno4, Rosa Nieto-Royo5, Annie Navarro-Rolon6, Concepción Prados-Sánchez7, Oriol Sibila8, Miguel-Ángel Martínez-García9.   

Abstract

BACKGROUND: Health-related quality of life (QoL) is one of the most important end points in bronchiectasis (BE). However, the majority of health-related QoL questionnaires are time-consuming or not validated in BE. The COPD Assessment Test (CAT) is an easy-to-use questionnaire. The objective of this study was to perform a complete validation of the CAT in BE.
METHODS: This was an observational, multicenter, prospective study in patients with BE. Psychometric properties of the CAT were measured: internal consistency (Cronbach α), repeatability (test-retest; intraclass correlation coefficient), discriminant validity (correlation with severity scores), convergent validity (correlation with some validated QoL questionnaire and other clinical variables of interest), longitudinal validity (measuring before and after each exacerbation during follow-up to determine the sensitivity to change and responsiveness), predictive validity to future exacerbations, and finally minimum clinically important difference.
RESULTS: Ninety-six patients were included and followed up for 1 year. Their mean age was 62.2 (15.6) years (79.2% women). The CAT showed excellent internal consistency (α, 0.95) and repeatability (intraclass correlation coefficient, 0.95). The validity of the CAT was excellent in all the measures (almost all with a Pearson coefficient > 0.40) except for the correlations with severity scores (Pearson coefficient between 0.22 and 0.26). Sensitivity to change before and after exacerbations was set at between 5.4 and 5.8 points. A CAT value ≥ 10 points showed prognostic value for patients with more than one exacerbation, and finally the minimum clinically important difference was set at 3 points.
CONCLUSIONS: The CAT presented excellent psychometric properties and is a questionnaire that is easy to use and interpret in patients with BE.
Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  COPD Assessment Test; bronchiectasis; quality of life

Year:  2019        PMID: 31446064     DOI: 10.1016/j.chest.2019.08.1916

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  Validation of the COPD Assessment Test (CAT) as an Outcome Measure in Bronchiectasis.

Authors:  Simon Finch; Irena F Laska; Hani Abo-Leyah; Thomas C Fardon; James D Chalmers
Journal:  Chest       Date:  2019-11-12       Impact factor: 9.410

2.  Impact of the SARS-CoV-2 Virus Pandemic on Patients with Bronchiectasis: A Multicenter Study.

Authors:  Adrián Martínez-Vergara; Rosa Mª Girón Moreno; Casilda Olveira; María Victoria Girón; Adrián Peláez; Julio Ancochea; Grace Oscullo; Miguel Ángel Martínez-García
Journal:  Antibiotics (Basel)       Date:  2022-08-12

3.  Psychometrics of health-related quality of life questionnaires in bronchiectasis: a systematic review and meta-analysis.

Authors:  Rebecca H McLeese; Arietta Spinou; Zina Alfahl; Michail Tsagris; J Stuart Elborn; James D Chalmers; Anthony De Soyza; Michael R Loebinger; Surinder S Birring; Konstantinos C Fragkos; Robert Wilson; Katherine O'Neill; Judy M Bradley
Journal:  Eur Respir J       Date:  2021-11-11       Impact factor: 16.671

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.